Navigation Links
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
Date:8/6/2009

The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding. The ATRI will also serve as a hub for more than 30 organizations, researchers and scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. The announcement of the ATRI was made during the Angelman Syndrome Foundation's biennial conference in Orlando, Fla.

Orlando, FL (PRWEB) August 6, 2009 -- The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding.

News Facts Related to Angelman Syndrome and the ATRI:
- Angelman Syndrome (AS) occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders.

- ATRI will realize the Angelman Syndrome Foundation's "scientific roadmap," which will help direct its aggressive funding of AS research.

- Short term focus of the roadmap is to fund research that finds treatments that may cure symptoms of AS while continuing ongoing research and clinical trials involving UBE3A, the abnormal gene in AS patients.

- Research funding will also focus on new therapies for symptoms, pharmaceuticals, biological agents, adaptive devices, surgical and diagnostic procedures.

- An emphasis on adult AS patients will extend the scope of clinical trials to include a wide age group and investigate and advance life and self-help skills, vocational training, and access to community programs and health services.

- ATRI will allow scientific members to conduct Web-based meetings and symposiums, and convene as necessary to discuss research progress and activities.

- Since AS shares symptoms with several other disorders, including autism, cerebral palsy, epilepsy, Rett Syndrome, and Prader-Willi Syndrome, any progress toward treating and curing symptoms has the potential to positively affect more than 12 million people.

Quotes Attributed to Michael D. Ehlers, M.D., Ph.D., Department of Neurobiology at Duke University Medical Center:
- "The creation of the Angelman Treatment and Research Institute is exciting and timely.
- "The priorities as established by the ATRI are right on in recognizing the continued need for expanding our fundamental knowledge of UBE3A and its role in brain development and function."
- "The Angelman Syndrome Foundation is to be applauded for having the vision to recognize the critical importance of basic research and in setting this research on a trajectory toward a cure."
- "I see a future of great opportunity and advance in neurodevelopmental disorders with Angelman Syndrome and the ATRI leading the way."

Quotes Attributed to Eileen Braun, Angelman Syndrome Foundation Executive Director
- The Angelman Syndrome Foundation is committing $125,000 in seed funding to start ATRI with an ultimate goal of raising $2 million within two years.
- Funding will be used to implement program goals while the Angelman Syndrome Foundation's Scientific Advisory Committee will continue administering grant reviews and making funding recommendations for innovative research.

Related Links:
Angelman Syndrome Foundation Web site
Researcher Endorsements of the ATRI
Angelman Syndrome Foundation Videos

About Angelman Syndrome:
Identified by Dr. Harry Angelman, AS occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders. It is a life-long neuro-genetic disorder usually identified in patients between two and five years old. AS is often misdiagnosed as autism and a cure has not yet been developed.

About Angelman Syndrome Foundation:
The Angelman Syndrome Foundation, the leading resource for AS information, support and AS research funding was founded more than 20 years ago with the mission of advancing the awareness and treatment of AS through education and information, research and support for individuals with AS, their families and other concerned parties. Since 1996 the Angelman Syndrome Foundation has funded 51 research grants totaling over $2.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($2.2 million) beginning in 2005. In November 2008, the Angelman Syndrome Foundation received Charity Navigator's 4-star rating for sound fiscal management. Only a quarter of all charities evaluated by Charity Navigator receive this distinction of demonstrating the ability to efficiently manage and grow its finances.

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2706254.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
2. Diabetes appears to increase risk of death for patients with acute coronary syndromes
3. Eye-staining technique offers early detection for dry eye syndrome
4. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Stem cell research produces a key discovery for Fragile X Syndrome
7. Metabolic syndrome heightens risk for development of uric-acid kidney stones
8. Stomach Virus a Culprit in Chronic Fatigue Syndrome
9. Chronic fatigue syndrome linked to stomach virus
10. Toward a faster prenatal test for Down syndrome
11. Brain Defect Helps Drive Fragile X Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: